A scoping review on AI-based retinal imaging found strong potential to assess brain health and related neurodegenerative and cerebrovascular diseases, positioning the retina as an accessible window into Disease of the nervous system. But the review also concluded that clinical adoption is limited by missing benchmark datasets, weak standardization, and the need for real-world validation, workflow integration, and regulatory guardrails.

Why It Matters To Your Practice

• Retinal imaging could expand beyond eye disease to help identify markers linked to brain health, neurodegeneration, and cerebrovascular risk.

• For clinicians, that raises the possibility of earlier, lower-burden screening using tools already familiar in ophthalmic and some primary care settings.

• The catch: promising models are not yet the same as practice-ready tools.

Clinical Implications

• Expect growing interest in retinal AI as a triage or risk-stratification aid rather than a standalone diagnostic test.

• Before adoption, clinicians will need evidence that models perform reliably across real-world populations, imaging devices, and care settings.

• Implementation will also depend on transparent outputs, workflow fit, reimbursement pathways, and regulatory clarity.

Insights

• The review frames oculomics as a fast-growing field that uses ocular imaging markers to infer systemic disease, including brain-related conditions.

• Authors propose an ecosystem for deployment that includes standardized benchmarks, interdisciplinary collaboration, cost-effectiveness analysis, and viable business models.

• Bottom line from the paper: technical promise is ahead of the infrastructure needed for routine care.

The Bottom Line

• Retinal AI may become a practical window into brain health, but clinicians should view current tools as emerging—not established—until standards, validation, and implementation pathways catch up.